关键词: 脑缺血; 组织型纤溶酶原激活物; 基质金属蛋白酶9; 依达拉奉

Abstract: 【Abstract】 Objective To study the protection mechanism of Edaravone following thrombolytic therapy in rt-PA against focal cerebral ischemia reperfusion injury in rats.Methods A rat model of embolic stroke was set up in each of the rats of groups embolizing the middle cerebral artery by thrombus(MCAO). 112 SD rats were randomly divided into 4 groups: A the sham operation group(n=28), B the model group without treatment(n=28), C rt-PA group(n=28), D combined edaravone with rt-PA group (n=28). The infarction volume of brain was investigated by 2, 3, 5-Triphenyl tetrazolium chloride (TTC) coloring and the neurologic deficit scores of rats were documented. The histological morphological damage of brain was investigated by hematoxylin-eosin (HE) staining. The expression of matrix MMP-9 in brain tissue was observed by immunohistochemistry method.Results Contrast to group B, the volume of brain infarction in rats of group C was obviously smaller (P<0.01), the score of neurologic impairment assessment was lower(P<0.05), the expression of MMP-9 was obviously decreased(P<0.05); Contrast to group C, the volume of brain infarction in rats of group D was obviously smaller(P<0.01), the score of neurologic impairment assessment was lower(P<0.05), the expression of MMP-9 was obviously decreased(P<0.05).Conclusion It is assumed that combination Edaravone with rt-PA thrombolysis may inhibit MMP-9 expression, then relieve the damage of reperfusion to BBB, and may prolong the thrombolytic therapeutic time window. Our study suggest that Edaravone could be potent neuroprotector against brain ischemia injury.

Key words: 【Key Words】 Brain ischemia; Tissue plasminogen activator; Matrix metalloproteinase 9; Edaravone